Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Q3 2023 Earnings Presentation
8 slides from Genedx's earnings presentation, Oct 30, 2023
Slide 1: GeneDx: One Test: Miss Less. Discover More.
1 Confidential and Proprietary; Do Not Distribute October 30, 2023 GeneDx NASDAQ: WGS One Test: Miss Less. Discover More. Exhibit 99.2
Slide 2: Disclaimer
2 Disclaimer This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, fo
Slide 3: Our Mission
3 Our Mission: Deliver personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery.
Slide 4: 3Q 2023 and Recent Highlights
3Q 2023 and Recent Highlights 4 Grew whole exome and genome test volume by 71% year-over-year $164M in pro forma cash, cash equivalents, marketable securities and restricted cash as of 9/30/23; after $48.8M net financing proceeds received on October 27, 2023 Expanded adjusted gross margins to 48% i
Slide 5: Test Mix Continues to Shift with Growth in WES/WGS Volume
Test Mix Continues to Shift with Growth in WES/WGS Volume 5 WES/WGS tests grew to 13,216 +71% year-over year and +11% vs Q2 $171.0M 2022 total revenue 39% adj gross margin The unadjusted and adjusted results from continuing operations for the applicable quarters include the combination of results fr
Slide 6: Revenue Growth driven by WES/WGS
Revenue Growth driven by WES/WGS 6 $171.0M 2022 total revenue 39% adj gross margin The unadjusted and adjusted results from continuing operations for the applicable quarters include the combination of results from the Legacy GeneDx diagnostic business with the data and information business of Legacy
Slide 7: Our path to profitability
Our path to profitability Rationalizing Operating Expense ▪ Removing $40 million in specifically identified operating costs, with all remaining investments focused on exome volume and revenue growth Revenue Growth ▪ Revenue growth driven by whole exome/genome testing ▪ Exome revenues, adjusted for a
Slide 8: 2023 Guidance Updated October 30, 2023
Revenues between $187-192 million for full year 2023 Expanded adjusted gross margin profile 2023 and beyond Expects to use $75 to $79 million of net cash for the second half of 2023, inclusive of servicing obligations of the previously exited business activities Expected to turn profitable in 2025 2